| October 1 |
Halozyme Presents Phase 2 Results for Regular Insulin-PH20 Confirming Faster Insulin Absorption and Superior Glucose Control |
| October 1 |
Bristol-Myers Squibb and ZymoGenetics to Present Final Phase Ib Data on PEG-Interferon Lambda at AASLD 2009 |
| October 1 |
WILEX AG: Preliminary data of MESUPRON show impressive increase in overall survival of patients with pancreatic cancer |
| October 1 |
XOMA Presents Results Demonstrating Novel Mechanism of Action for XOMA 052 in Regulating IL-1 Beta Levels |
| October 1 |
Study Shows AFRESA Provides Rapid Suppression of Endogenous Glucose Production in Diabetes Patients |
| October 1 |
Scientists Report Impressive Research Results with Tβ4 on First Day of Thymosin Meeting |
| October 1 |
Positive Interim Data from Minnow Medical Peripheral Artery Disease Trial Presented at TCT 2009 Conference |
| October 1 |
BreastCancerTrials.org and Largest Breast Cancer Trial Announced |
| October 1 |
Drug That Crosses Blood-Brain Barrier Reduces Formation Of Brain Metastases In Mice |
| October 1 |
Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer |
| October 1 |
Sanofi Pasteur Announces Results of U.S. Clinical Trials in Adults Following One Dose of Influenza A (H1N1) Vaccine |
| October 2 |
Updated Advaxis Phase I Survival Data Indicates Long-Term Immune Protection |
| October 2 |
RegeneRx's Tβ4 Significantly Improves Functional Recovery in Multiple Sclerosis Animal Model |
| October 2 |
Additional Analysis Confirms Significant Symptomatic Benefit of Droxidopa in Treatment of Neurogenic Orthostatic Hypotension |
| October 2 |
LifeCycle Pharma Announces Positive Results from a 12 Month Extension Phase of the Phase 2 Clinical Study of LCP-Tacro Once Daily in Stable Liver Transplant Patients |
| October 2 |
Ardea Biosciences to Present Results from a Phase 2a Study of RDEA594 at the 2009 ACR/ARHP Annual Scientific Meeting |
| October 2 |
ImmunoCellular Therapeutics' Antibody Shows Promise in Detecting Pancreatic and Lung Cancer in Serum Test |
| October 2 |
Dapagliflozin Study Demonstrated Significantly Improved Glycemic Control and Weight Reduction in Type 2 Diabetes Patients Inadequately Controlled with Metformin |
| October 2 |
AFRESA Phase 3 Data Show Sustained Glycemic Control, Normal Lung Function in Patients over Four Years of Treatment |
| October 2 |
Compelling new data on Novartis' oral MS therapy |
| October 2 |
Immutep Announces Final Results In Advanced Renal Cell Carcinoma |
| October 2 |
KYTHERA Biopharmaceuticals Presents Positive Data From Two Phase 2 Studies With ATX-101 |
| October 2 |
Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera for Gaucher Disease |
| October 2 |
Video: New Analysis Supports Tolerability of Lexiscan (regadenoson) Injection for Pharmacologic Myocardial Perfusion Imaging Studies |
| October 2 |
Array BioPharma to Present Clinical Results on Diabetes Drug at European Diabetes Meeting |
| October 2 |
Intercept Pharmaceuticals' FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease |
| October 3 |
Newly Published Phase III Data Show Novartis Drug Sandostatin LAR Depot Reduced Risk of Disease Progression by 66% in Advanced NET Patients |
| October 3 |
OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer |
| October 3 |
KYTHERA Biopharmaceuticals Announces Presentation of Phase 2 Data on Novel Fat Reduction Drug at ASDS Meeting |
| October 3 |
Ulcerative Colitis Treatment Reduces Need for Surgery by Almost Half |
| October 3 |
InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting |
| October 3 |
Orexigen Therapeutics Phase 2b Trial for Empatic Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients |
| October 3 |
InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting |
| October 4 |
Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer |
| October 4 |
Superior Efficacy-dose Ratio for Lantus Over detemir |
| October 4 |
AEterna Zentaris: Thorough QT Trial with Cetrorelix in Benign Prostatic Hyperplasia Meets Primary Endpoint |
| October 5 |
Promising Clinical Data with RegeneRx's Tβ4 Drug Candidates Presented on Second Day of Thymosin Meeting |
| October 5 |
Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R) |
| October 5 |
Two Phase III Studies of Lucentis Show Early and Sustained Improvement in Vision in Patients with Retinal Vein Occlusion |
| October 5 |
Study Finds That Onglyza (saxagliptin) When Added To Metformin Was Non-Inferior To JANUVIA (SITAGLIPTIN) When Added To Metformin In Reducing Hemoglobin (HbA1c) In Adults With Type 2 Diabetes Mellitus |
| October 5 |
Positive Phase II Results for GSK1838262 (XP13512) Reported for Subjects with Post-Herpetic Neuralgia and a History of Inadequate Response to Gabapentin |
| October 5 |
Depomed, Inc. Announces Positive Top-Line Results from Phase 3 Clinical Trial of DM-1796 in Postherpetic Neuralgia |
| October 5 |
Avila Presents Preclinical Data on its Novel, Orally-Available, Pan-Genotype Protease Inhibitor, AVL-181, Demonstrating Protein Silencing of Hepatitis C Virus |
| October 5 |
Long-Term Data from Landmark Phase 3 Safety and Nutritional Study Evaluating Alnara Pharmaceuticals' Liprotamase in Patients with CF to be Presented at 2009 North American Cystic Fibrosis Conference |
| October 5 |
Nymox Announces New Pooled Analysis Confirms 12 Month Benefit of NX-1207 Treatment for BPH |
| October 5 |
Cocaine Vaccine Shows Promise for Treating Addiction |
| October 5 |
ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) |
| October 5 |
Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial |
| October 5 |
Molecular Insight Pharmaceuticals Presents Azedra Efficacy Data in Neuroendocrine Tumors |
| October 6 |
Immutep Announces New Interim Results In Phase I/II Chemoimmunotherapy Trial In Breast Cancer |
| October 6 |
Antidepressant Use During Pregnancy Associated With Some Adverse Outcomes in Newborns |
| October 6 |
AVANIR to Present Pivotal Zenvia Phase III Data at American Neurological Association and World Congress on Controversies in Neurology Annual Meetings |
| October 6 |
Merz Pharmaceuticals Announces Phase III Data for NT 201 in Post-stroke Upper Limb Spasticity |
| October 6 |
Topical NSAID Shows Positive Result in Phase III trial |
| October 6 |
TOPICA Announces Positive Phase 2 Clinical Results for Luliconazole, a Potent Topical Antifungal |
| October 7 |
IDEA updates on Diractin (ketoprofen in TransfersomeR gel) status |
| October 7 |
Vical's TransVax CMV Vaccine Elicits Long-Term Immune Responses in Phase 2 Trial |
| October 7 |
Repros Reports Androxal Restores Normal Sperm Counts While Increasing Testosterone Levels in Hypogonadal Men |
| October 7 |
Early Treatment With Glatiramer Acetate Reduces Risk Of Progressing To ?Full-Blown? Multiple Sclerois By Almost Half (PreCISe study) |
| October 7 |
Transdel Pharmaceuticals Announces Positive Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel |
| October 7 |
Data From a Head-to-Head Crossover Study Evaluating FOSRENOL and Sevelamer Published Today |
| October 8 |
MacuCLEAR and Mystic Successfully Complete Phase Ib Clinical Trial for Macular Degeneration |
| October 8 |
Antisoma plc (UK) - Antisoma to amend ACCEDE phase III study of AS1413 |
| October 8 |
Short Strand Of RNA May Help Predict Survival And Response To Treatment For Patients With Liver Cancer |
| October 8 |
Panenza and Humenza Influenza A(H1N1) Vaccines Demonstrate Robust Immune Response After One Dose |
| October 8 |
Advaxis Live Listeria Vaccine Induces Epitope Spreading |
| October 9 |
Angiochem to Present New Clinical Data for ANG1005 in Brain Cancers at Society for Neuroscience Meeting |
| October 9 |
AVANIR Pharmaceuticals Presents Zenvia Phase III Results in Multiple Sclerosis Patient Population at Controversies in Neurology Congress |
| October 9 |
Results Published In Journal of Cystic Fibrosis Confirm Creon (pancrelipase) Delayed-Release Capsules Improves Fat Absorption in Patients With Cystic Fibrosis |
| October 12 |
Depomed Reports Results From Two Phase 3 Clinical Trials Evaluating Non-Hormonal Therapy for Menopausal Hot Flashes |
| October 12 |
Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) |
| October 12 |
Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix |
| October 12 |
NOXXON Pharma AG Announces Excellent Preliminary Phase I Trial Results for Spiegelmer NOX-E36 ? Good Safety and Pharmacodynamic Profile and Additional Good Subcutaneous Bioavailability |
| October 12 |
Synta Pharmaceuticals Announces Updated Elesclomol SYMMETRY Data Presented at Melanoma XIII |
| October 12 |
Avodart (dutasteride) in combination with tamsulosin shows benefits for men with benign prostatic hyperplasia (enlarged prostate) |
| October 12 |
Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine |
| October 13 |
New Study Assesses Skin Hydration And Epidermal Function Of 2.5% And 5% Benzoyl Peroxide-Clindamycin Combinations |
| October 13 |
Alkermes Announces Positive Results From Two Clinical Trials of ALKS 33 |
| October 13 |
GSK?s Avodart / tamsulosin combination showed benefits for men with prostate enlargement |
| October 13 |
Argos Therapeutics to Present Positive Immune Response and Viral Load Data for Arcelis HIV Program at the AIDS Vaccine 2009 Conference |
| October 13 |
Metabolex Announces Positive Phase 1 Clinical Trial Results of MBX-2982 |
| October 13 |
AVANIR Pharmaceuticals Presents Detailed Zenvia Confirmatory Phase III Results in Late-Breaker Session at American Neurological Association Meeting |
| October 14 |
Ziopharm Announces Positive Palifosfamide Sarcoma Randomized Phase II Interim Data: Trial Enrollment Stopped Early |
| October 14 |
Advanced U.S. Clinical Trial Confirms Single-Agent Efficacy of Rexin-G in Metastatic Pancreas Cancer: All Endpoints Achieved |
| October 14 |
New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met (pioglitazone HCl and metformin HCl) as Initial Therapy Compared to Either Component Alone |
| October 15 |
Surgeons Discover That Common Anti-Clotting Drug May Cause Problems for Some Trauma Patients |
| October 15 |
NanoBio's Nanoemulsion Kills Drug-Resistant Bacteria Found in Cystic Fibrosis Patients |
| October 15 |
KaloBios' KB001 Antibody Shows Encouraging Safety and Activity in New Approach to Fighting Pseudomonas Infection in Cystic Fibrosis Patients |
| October 15 |
Inspire Announces Presentation at the North American Cystic Fibrosis Conference and Provides Enrollment Update for Phase 3 Cystic Fibrosis Trial |
| October 15 |
Protalix BioTherapeutics Announces Positive Top-line Results from its Phase III Clinical Trial of UPLYSO for the Treatment of Gaucher Disease |
| October 15 |
Human Genome Sciences to Host November 2nd Conference Call to Discuss Top-Line Results from Second Phase 3 Trial of Benlysta (Belimumab) in Systemic Lupus Erythematosus |
| October 15 |
Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program |
| October 15 |
CREON (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis |
| October 16 |
Interim analysis of an ongoing phase II study with nicotine vaccine shows primary endpoint not achieved |
| October 16 |
Study Results Suggest Oral Salmon Calcitonin Using Eligen Drug Delivery Technology May Reduce Cartilage and Bone Degradation in Osteoarthritis |
| October 16 |
Targacept Presents Data from Highly Successful Phase 2b Trial of TC-5214 as Augmentation Treatment for Major Depressive Disorder |
| October 18 |
Forest Laboratories and Cypress Bioscience Announce Study Shows Patients Treated with Savella Experience Improvements in Pain and Physical Function |
| October 18 |
Uloric (febuxostat) Demonstrated Efficacy for Management of Hyperuricemia in Patients with Gout |
| October 18 |
UCB's Cimzia (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis |
| October 19 |
Angiochem's ANG1005 Demonstrates Safety and Efficacy in Phase 1/2 Brain Cancer Studies |
| October 19 |
Ardea Biosciences Announces Additional Positive Results from a Phase 2a Study of RDEA594 at the 2009 ACR/ARHP Annual Scientific Meeting |
| October 19 |
BENZEFOAM Emollient Foam Demonstrates Significant Reduction in Propionibacterium acnes in Study Presented at the Fall Clinical Dermatology Conference |
| October 19 |
Alnara Pharmaceuticals' Liprotamase Demonstrates Long-Term Safety & Maintenance of Nutritional Status in Patients with CF; Results of Landmark Phase 3 Safety Study Reported |
| October 19 |
Rexahn Reports Positive Top-line Phase IIa Data for Serdaxin in Patients with Major Depressive Disorder (MDD) |
| October 19 |
Study Shows Good Response for New Drug in Patients with Rheumatoid Arthritis |
| October 19 |
Transave Completes Successful Phase II Clinical Program for Arikace in the Treatment of Pseudomonas Lung Infections |
| October 19 |
Trubion Pharmaceuticals, Inc. Reports Positive Data from Phase 2b Re-treatment Study of TRU-015 |
| October 19 |
Schering-Plough Highlights Boceprevir, Narlaprevir (SCH 900518) and Pegintron Data at the American Association for the Study of Liver Diseases (AASLD) 2009 Annual Meeting |
| October 19 |
Oxford Biomedica Announces Update On Prosavin Phase I/Ii Trial In Parkinson's Disease And Publication Of Preclinical Results |
| October 20 |
Human Genome Sciences and GlaxoSmithKline Announce Full Presentation at ACR of Positive Phase 3 Study Results for Benlysta in Systemic Lupus Erythematosus |
| October 20 |
BioSante Pharmaceuticals Reports Positive LibiGel Safety Data in Phase III Program |
| October 20 |
Data Analysis Reinforces the Safety Profile of Levemir |
| October 20 |
New Study Assesses Skin Hydration and Epidermal Function of 2.5% and 5% Benzoyl Peroxide-Clindamycin Combinations |
| October 20 |
Updated Data from Randomized Controlled Phase II Study Evaluating Oral Apremilast in Psoriatic Arthritis Demonstrates Sustained Response at Six Months |
| October 20 |
ORENCIA (abatacept) Demonstrated Sustained Clinical Response in a Study of Adult Patients with Moderate to Severe Early Rheumatoid Arthritis (Less Than Two Years Duration) |
| October 20 |
Calistoga Pharmaceuticals Presents Interim Clinical Efficacy Results from Ongoing Clinical Trial of CAL-101 at the International Workshop on Chronic Lymphocytic Leukemia |
| October 20 |
Idera Pharmaceuticals Presents Preclinical Data at ACR/ARHP 2009 Annual Meeting on IMO-3100, a Toll-Like Receptor Antagonist, in Combination with Enbrel in Arthritis Model |
| October 20 |
Study Results: Novel Oral PTH Formulation Using Emisphere's Eligen Technology Showed Potential Therapeutical Advantages to Available Injectable PTH in Postmenopausal Osteoporotic Women |
| October 21 |
"Monoclonal antibody BT-061 shows efficacy in patients with rheumatoid arthritis" |
| October 22 |
Aerie Pharmaceuticals' ROCK Inhibitor, AR-12286, Demonstrates Positive Results in Glaucoma Patients in a Phase 2a Study |
| October 22 |
CombinatoRx'S Synavive (CRx-102) Maintains Efficacy Throughout 12 Month Phase 2 Knee OA Extension Trial |
| October 22 |
Argos Therapeutics Presents Positive Phase 2 Viral Load and Immune Response Data for Arcelis HIV Program at the AIDS Vaccine 2009 Conference |
| October 22 |
Teva Comments on Positive Results of Phase III Trial in MediWound's Debrase |
| October 22 |
AcelRx Announces Positive Results from a Phase 2 Study of ARX-03, a Sufentanil/Triazolam NanoTab for Procedural Sedation, Anxiolysis & Analgesia |
| October 22 |
Medtronic Highlights Positive ONSET Pediatric Diabetes Trial Results |
| October 22 |
Aeolus Drug Protects the Gastrointestinal Tract in Acute Radiation Syndrome Studies Sponsored by the National Institutes of Health's National Institute for Allergy and Infectious Diseases |
| October 23 |
Halozyme Study Results Show Faster Insulin Absorption when Administered in Combination with a Wide Range of PH20 Enzyme Concentrations |
| October 23 |
Lubris, Biomodels Report on Potential New Therapy for Osteoarthritis |
| October 23 |
New Data Presented at ACR Meeting Demonstrates Colcrys (Colchicine, USP) Significantly Reduces Pain of Acute Gout Flare Within 24 Hours With Side Effects Comparable to Placebo |
| October 23 |
New Simponi Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis |
| October 23 |
Newly Published Clinical Data Shows Caldolor (Ibuprofen) Injection Reduces Opioid Use While Improving Pain Relief in Post-Operative Patients |
| October 23 |
Patients Taking Vimovo Showed a Decrease in Incidence of NSAID-Associated Ulcers |
| October 23 |
Detailed Results from RV 144 HIV Vaccine Trial Published Today in The New England Journal of Medicine and Presented at the AIDS Vaccine 2009 Conference Provide Insight for Future Research |
| October 23 |
NicOx presents 26 week naproxcinod efficacy data at American College of Rheumatology |
| October 23 |
Novartis drug Tasigna meets primary endpoint in pivotal trial against Gleevec as first-line treatment in chronic myeloid leukemia patients |
| October 23 |
New Phase II data show ACZ885 gave better pain relief and flare prevention for patients with chronic gout than an injectable corticosteroid |
| October 23 |
TransMolecular's 131I-TM601 Shown to Improve Survival in Recurrent Malignant Glioma |
| October 23 |
Exelixis and Bristol-Myers Squibb Report New Phase 2 Data for XL184 in Patients With the Most Common and Aggressive Form of Brain Cancer |
| October 23 |
KYTHERA Biopharmaceuticals Announces Two Data Presentations on Its Novel Fat Reduction Drug at ASPS Meeting |
| October 23 |
Research Into Cancer During Pregnancy: Treating Pregnant Women With Chemotherapy has no Detrimental Effect on the Foetus |
| October 23 |
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Patients With Non-Responsive Thyroid Cancer |
| October 23 |
Shire Announces New Data on Pharmacokinetics of Vyvanse |
| October 23 |
TargeGen Announces Successful Completion of Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients |
| October 23 |
Interim Clinical Trial Results Show MedImmune's H1N1 Vaccine Has Similar Safety Profile as Seasonal Vaccine in Eligible Children and Adults |
| October 24 |
Landmark Study Shows Substantial Improvement in Survival and Renal Recovery for Acute Kidney Injury Patients Treated With CRRT |
| October 24 |
New Study Results Show That Patients Have Higher Treatment Satisfaction With Liraglutide Compared to Exenatide |
| October 24 |
Bleeding is Rare in IVF Patients Who Become Pregnant When Treated with a Combination of Vaginal Progesterone Gel and Estrogen |
| October 24 |
The risk of venous thromboembolism for drospirenone containing oral contraceptives is comparable to the risk of other oral contraceptives available on the market |
| October 24 |
Orexigen Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk |
| October 25 |
New Animal Study Featured in the Journal of Cellular Biochemistry Supports Rexahn's Archexin as Potent Inhibitor of Human Cancer Cell Growth |
| October 25 |
Study Demonstrates Livalo Is an Efficacious Treatment for Achieving Lipid Goals |
| October 26 |
NPS Reports Two Teduglutide Abstracts Accepted for Presentation at American College of Gastroenterology Annual Scientific Meeting |
| October 26 |
Positive Data from Two Investigator-Initiated Studies with Santarus' ZEGERID to Be Presented At ACG |
| October 26 |
Data Presented On Oncophage Cancer Vaccine In Recurrent Glioma At Sno 2009 |
| October 26 |
Vical's Vaxfectin Adjuvant Drives 200-Fold Increase in Antibody Responses With Sanofi-Pasteur Fluzone Seasonal Influenza Vaccine |
| October 26 |
Theratechnologies: International Workshop on Adverse Drug Reactions and Co-morbidities in HIV |
| October 26 |
ImmunoCellular Therapeutics to Present Today Data From Phase I Clinical Trial of ICT-107 at Annual Meeting of Congress of Neurological Surgeons |
| October 26 |
New Study Results Analyzed the Use of Kapidex (dexlansoprazole) for Nighttime Heartburn in Adults with Non-Erosive GERD |
| October 26 |
Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users |
| October 26 |
Inhibitex Announces Data Presentation at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) |
| October 26 |
Salix Pharmaceuticals Previews American College of Gastroenterology 2009 Annual Scientific Meeting |
| October 26 |
Halsa Pharmaceuticals Announces ZAG Demonstrates Weight Loss, Rise in Temperature and Reduction of Diabetes Symptoms in Preclinical Studies at Obesity 2009 Annual Scientific Meeting |
| October 26 |
New Data Presented From WELCOME Trial Show Positive Impact of Cimzia (certolizumab pegol) on Hospitalizations and Surgeries in Patients With Prior Infliximab Failure |
| October 26 |
Data Demonstrate That GATTEX(Teduglutide) Improves Lean Body Mass, Mineral Composition and Electrolyte Levels in Patients with Parenteral Nutrition Dependent Short Bowel Syndrome |
| October 26 |
Creon (pancrelipase) Delayed-Release Capsules Improves Digestive Outcomes In Adults With Chronic Pancreatitis |
| October 26 |
Shire Presents Results of Five Lialda (mesalamine) Analyses at ACG 2009 Annual Scientific Meeting |
| October 27 |
Icagen Reports Top-line Results of Phase IIa Study of Senicapoc in Exercise-Induced Asthma |
| October 27 |
New Data From Arena Pharmaceuticals' Pivotal BLOSSOM Trial of Lorcaserin Demonstrate Improvements in Patients' Body Composition, Cardiovascular Risk Factors and Quality of Life |
| October 27 |
Orexigen Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society |
| October 27 |
Phase 2 Data From Oral NKTR-118 Presented at American College of Gastroenterology in San Diego |
| October 27 |
Isotechnika Pharma Announces Voclosporin Presentations at American Academy of Ophthalmology |
| October 27 |
Results of Phase I Study Show Novel, Investigational PA65020 Compound Significantly Decreased Risk of Upper GI Damage in Healthy Adults |
| October 27 |
PolyMedix Completes Successful Phase 1B Clinical Study of Heparin Antagonist PMX-60056 |
| October 27 |
ImmunoCellular Therapeutics Presents Data from Phase I Trial of ICT-107 Demonstrating Significant Increase in Tumor-Free Progression in Patients with Brain Cancer |
| October 27 |
Logical Therapeutics Announces Positive Results of LT-NS001 vs. Naproxen Clinical Study |
| October 28 |
Interim Results from Study 107 Highlight the Potential Role of Telaprevir-Based Regimens in HCV Patients Who Failed Prior Treatment |
| October 28 |
New Data Supports Pharmacoeconomic Benefits of Ceplene |
| October 28 |
Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis |
| October 28 |
Study demonstrates effectiveness of once-daily dose of Asacol for ulcerative colitis |
| October 28 |
Updated European guidelines highlight benefits of Rasilez, the only approved direct renin inhibitor, in treating high blood pressure |
| October 28 |
SCYNEXIS to Present HCV Data on Novel Cyclophilin Inhibitor SCY-635 at AASLD Annual Meeting |
| October 28 |
Forest Laboratories, Inc. and Gedeon Richter Announce Positive Results from a Phase IIb Study of Cariprazine for the Treatment of Schizophrenia |
| October 28 |
Difficult-to-Treat Patient Populations Respond Positively to Hepatitis C Treatment |
| October 29 |
Genta Announces Top-Line Results of AGENDA Phase 3 Trial of Genasense in Patients with Advanced Melanoma |
| October 29 |
Celldex Therapeutics Presents Positive Clinical Data from Phase 1 Studies of Antibody-Based Cancer Vaccine Candidate, CDX-1307 |
| October 29 |
Genta Incorporated Announces Conference Call to Review Top-Line Results of AGENDA Phase 3 Trial of Genasense in Patients with Advanced Melanoma |
| October 29 |
Subset Data from Two Randomized Phase 3 Trials Show TYSABRI Significantly Reduces Rates of Hospitalization in Patients with Moderate-to-Severe Crohn's Disease |
| October 30 |
YM Biosciences Reports Additional Results From Nimotuzumab Phase III Study In Children With Glioma Presented By Oncoscience Ag |
| October 30 |
Data Presented on Cempra Pharmaceutical's CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates |
| October 30 |
Presentations of Cempra Pharmaceutical's CEM-102 (fusidic acid) at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA Candidate |
| October 30 |
Idenix Pharmaceuticals Presents Data on IDX184 for the Treatment of Hepatitis C Virus (HCV) |
| October 30 |
Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology |
| October 30 |
A Decade Later, Lifestyle Changes Or Metformin Still Lower Type 2 Diabetes Risk |
| October 30 |
Inappropriate Initial Antibiotic Treatment May Extend Stays for Patients with Healthcare-Associated Skin Infections |
| October 30 |
Affymax and Takeda Announce Preliminary Phase 2 Data Demonstrated That Hematide Increased Hemoglobin in Dialysis Patients |
